Integra LifeSciences Holdings Corporation reported second-quarter 2026 adjusted earnings per share of 56 cents, up 24.4% year over year and beating the Zacks Consensus Estimate by 16.7%, while revenues of $418.76 million rose 0.8% but missed consensus by 0.2%. The company's Specialty Surgery segment, which is part of its overall business, posted revenues of $309.3 million, up 1.7% on a reported basis, while Tissue Reconstruction revenues totaled $109.5 million, down 1.9% on a reported basis. Adjusted gross margin expanded 60 basis points to 61.3%, and adjusted EBITDA rose 10.1% to $78.4 million, with margin up 160 basis points to 18.7%. For full-year 2026, Integra reaffirmed its organic revenue growth guidance of 0.8% to 3.3% and expects adjusted earnings per share between $2.40 and $2.50, while for the third quarter it projects reported revenues of $410-$425 million and adjusted earnings of 53-61 cents per share. Since the earnings release, estimates have trended downward, and the stock holds a Zacks Rank #3 (Hold) with a VGM Score of C.
Integra LifeSciences HoldingsQ2 EPS beat and reaffirmed guidance despite revenue miss
Intuitive Surgical Inc